Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) gapped up before the market opened on Thursday after Deutsche Bank Aktiengesellschaft raised their price target on the stock from $40.00 to ...

Analysts have set 12-month price targets for Alkermes, revealing an average target of $42.0, a high estimate of $52.00, and a ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Thrivent Financial for Lutherans reduced its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 3.3% in the fourth ...

The 6th GxP Cloud Compliance Summit is uniting Life Science companies to manage data security risks, validate internal and ...

Data suggest that SC pembrolizumab is non-inferior to IV pembrolizumab in patients with newly diagnosed, advanced NSCLC.

Alkermes has said it is considering a spin-out ... to halt development of a BCL-2 inhibitor licensed from China's Fosun Pharma which had started phase 1 testing as a possible cancer drug, saying ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

Deutsche Bank analyst David Hoang raised the firm’s price target on Alkermes (ALKS) to $52 from $40 and keeps a Buy rating on the shares. After ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...